Breaking News, Financial News

Financial Report: Charles River Laboratories

Discovery and manufacturing services drive growth

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Charles River Laboratories 4Q Revenues: $329.5 million (+14%) 4Q Earnings: $27.7 million (+43%) FY Revenues: $1.3 billion (+11%) FY Earnings: $128.2 million (+23%) Comments: Research Models and Services (RMS) revenues were $117.7 million in the quarter, down 4% impacted by exchange rates.  Discovery and Safety Assessment (DSA) was $149.6 million, up 35% driven primarily by the Early Discovery acquisitions, which contributed 24%. Manufacturing revenue was $62.3 million in the quarter, up 11%...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters